One Year of JOURNAVX in Practice: Emerging Real-World Insights from the First Approved NaV1.8 Pain Therapy

9:00 am - Wednesday 27th January 2027

  • Review recently published real-world and Phase IV evidence evaluating JOURNAVX use in clinical practice
  • Examine emerging data on opioid-sparing outcomes and the evolving role of non-opioid therapies in acute pain management
  • Explore prescribing patterns and treatment utilization trends from the growing body of post-launch evidence
  • Discuss key considerations for advancing future pain therapies, including remaining challenges around efficacy, access, reimbursement, and demonstrating value beyond opioids

Speakers:

Senior Vice President & Disease Area Executive
Vertex Pharmaceuticals